Archives
-
ISRIB (trans-isomer): Memory Retention & ISR
2026-09-05
ISRIB (trans-isomer) is a brain-penetrant integrated stress response inhibitor with unusual value for separating memory retention from retrieval. This article translates recent epilepsy-associated forgetting research into practical assay logic for ER stress research, molecular validation, and cognitive models.
-
PD98059: Reading ERK Causality in Cell Injury
2026-09-04
PD98059 is a reversible MEK inhibitor that helps researchers distinguish ERK-dependent signaling from downstream oxidative and mitochondrial injury. This mechanistic guide uses hepatotoxicity research to refine assay design beyond standard proliferation and apoptosis workflows.
-
Red Blood Cell Lysis Buffer for Bone Research
2026-09-04
Turn crowded mammalian blood and tissue suspensions into cleaner, more reproducible inputs for flow cytometry, nucleic acid, protein, and cell-culture workflows. This guide shows how selective erythrocyte removal can support bone and immunology studies while preserving nucleated-cell quality.
-
Ampicillin sodium: Assay Workflows & Troubleshooting
2026-09-03
Build more reproducible antibacterial activity assays with a defined β-lactam mechanism, controlled dilution design, and stability-aware handling. This guide also shows how resistant-strain comparisons and recombinant selection workflows can extend the value of Ampicillin sodium beyond a single MIC endpoint.
-
TBK1, Microglia Pyroptosis, and Painful Diabetic Neuropathy
2026-09-03
Liao et al. identify TANK-binding kinase 1 (TBK1) as an upstream driver of painful diabetic neuropathy through activation of NF-κB, the NLRP3 inflammasome, and microglial pyroptosis. The study combines genetic, pharmacological, behavioral, vascular, and tissue-level analyses to support TBK1 inhibition as a mechanistically informed strategy for reducing diabetic pain and peripheral nerve injury.
-
Cannabidiol, Endocannabinoids, and Orofacial Pain
2026-09-02
This mouse study shows that cannabidiol reduces both inflammatory orofacial nociception and pain-associated affective and cognitive deficits through coordinated peripheral and central mechanisms. Its combination of behavioral profiling, molecular assays, and fiber photometry links FAAH–anandamide signaling with CB2-, CB1-, and serotonergic pathways, while also highlighting important limits for translation to human pain treatment.
-
MG-132 for Reliable Cell Viability Assays
2026-09-02
MG-132 (Z-LLL-al, SKU A2585) provides a practical, mechanism-based way to connect proteasome inhibition with apoptosis, cell-cycle arrest, and oxidative stress measurements. This scenario-driven guide explains dose selection, solvent handling, interpretation of viability data, and criteria for choosing a dependable research reagent.
-
CHIR-99021 (CT99021) for Stem Cell Workflows
2026-09-01
CHIR-99021 (CT99021) gives researchers a selective way to tune GSK-3α/β, stabilize β-catenin, and separate pathway timing from cell-fate outcomes. This guide translates that mechanism into practical stem cell, organoid, cardiac, neuronal, and thymocyte workflows, with assay controls designed around the reference study’s unexpected β-catenin turnover pathway.
-
Nile Red for Lipid Droplet Workflows
2026-09-01
Nile Red, or Nile blue oxazone, converts lipid storage into a practical two-channel imaging readout. This guide connects intracellular lipid droplet staining with oleic-acid lipid models, autophagy studies, quantitative analysis, and troubleshooting decisions.
-
HRP Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-08-31
Learn how HRP Goat Anti-Mouse IgG (H+L) Antibody, SKU K1221, can improve mouse-primary immunodetection workflows connected to cell viability, proliferation, and cytotoxicity studies. This scenario-based guide covers assay compatibility, optimization, interpretation, storage, and evidence-based reagent selection.
-
PPT (Propyl Pyrazole Triol) in ERα Assays
2026-08-31
A scenario-based guide to using PPT (Propyl Pyrazole Triol), a potent, selective ERα agonist, SKU B6735, in cell viability, proliferation, and cytotoxicity workflows. It covers receptor specificity, solvent compatibility, protocol controls, data interpretation, and practical vendor-selection criteria.
-
Cannabidiol, Endocannabinoid Signaling, and Orofacial Pain
2026-08-30
This 2026 Brain Research Bulletin study shows that cannabidiol (CBD) reduces both nociceptive and pain-related affective abnormalities in mouse inflammatory pain models. Its main contribution is a multi-level mechanism linking peripheral FAAH and CB2 signaling with central anandamide, CB1, and serotonin-related circuit changes.
-
Protease Inhibition and Blue Light Stomatal Opening
2026-08-29
Wang and colleagues used chemical screening to show that selected protease inhibitors suppress blue light-induced stomatal opening in Commelina benghalensis. The strongest inhibitors reduced plasma membrane H+-ATPase phosphorylation without disrupting phototropin activity or abscisic acid responses, revealing a previously unresolved regulatory branch in guard-cell signaling.
-
Recombinant Annexin V for Apoptosis Detection
2026-08-28
Brumatti, Sheridan, and Martin describe a practical bacterial-expression workflow for producing soluble, polyhistidine-tagged recombinant annexin V, followed by FITC conjugation and apoptotic-cell analysis. The study’s main contribution is methodological: it makes phosphatidylserine-exposure assays more accessible for flow cytometry and fluorescence microscopy while emphasizing the biological interpretation and limitations of annexin V binding.
-
Vancomycin in Microbiome–Immune Assay Design
2026-08-28
Vancomycin is more than a bacterial cell wall synthesis inhibitor: it can serve as a controlled perturbation in microbiome–immune research. This guide translates an allergic-rhinitis rat study into rigorous assay design while preserving the distinction between antibiotic effects and therapeutic conclusions.